News, Articles and Updates
Behavioral Health
Do Psychedelics Need a Rebrand Before Their Approval for Mental Health?
This is an exclusive BHB+ story. In 1969, the term “psychedelics” conjured images of San Francisco’s historic Hippie Hill, the Grateful Dead and Woodstock. Close to 60 years later, that stigma lingers despite a multitude of advancements and research showcasing the drug class’s potential in…
From Hospital to Outpatient Care After Long-Acting Injectable Antipsychotic Initiation in Bipolar Disorder: Nationwide Evidence From Taiwan
Original Source: Journal of Clinical Psychiatry, all rights reserved. — Bipolar disorder (BD) is a recurrent, episodic illness. Long-term pharmacotherapy is central to relapse prevention, yet treatment nonadherence is common and clinically consequential, as it is consistently linked to higher risks of relapse, hospitalization, and…
Cariprazine in the Treatment of Pediatric Patients With Irritability Associated With Autism Spectrum Disorder: A Randomized Controlled Trial
To evaluate the efficacy and safety of cariprazine in youth with irritability associated with autism spectrum disorder (ASD). — Excerpt from Journal of the American Academy of Child & Adolescent Psychiatry Read More
Psychedelics in Psychiatry: A Wakeup Call for Clinicians in the Age of Policy Reform
Original Source: Journal of Clinical Psychiatry, all rights reserved. — To the Editor: On April 18, 2026, President Donald Trump signed an executive order directing the US Food and Drug Administration (FDA) to fast-track review of psychedelic drugs, including psilocybin and ibogaine, and allocating $50…
When Hair Becomes Hazardous: Trichotillomania, Trichophagia, and Gastric Trichobezoar
Original Source: Journal of Clinical Psychiatry, all rights reserved. — Have you ever evaluated a patient with chronic abdominal pain, early satiety, nausea, vomiting, or weight loss and wondered whether an unrecognized psychiatric disorder might be contributing to the presentation? Have you seen patchy alopecia,…
Butorphanol Dependence in a Woman With No Prior Substance Use
Original Source: Journal of Clinical Psychiatry, all rights reserved. — Butorphanol is a synthetic opioid with partial agonist-antagonist receptor activity in the μ and ĸ receptors.1 It is approved by the US Food and Drug Administration as an analgesic. Because of the antagonist activity, the…
Thirty Years of the DCPR with Jenny Guidi, PsyD, PhD
Original Source: Journal of Clinical Psychiatry, all rights reserved. — Listen on your favorite platform Episode Overview Jenny Guidi, PsyD, PhD, associate professor of clinical psychology at the University of Bologna and director of psychometric and clinimetric studies at Massachusetts General Hospital, joins host Ben…
Executive order calls for creation of NIH Women’s Health Division
An executive order issued by the White House Oct. 19 directs the Department of Health and Human Services, through the National Institutes of Health, to establish a Women’s Health Division. The new division will focus on conditions that uniquely or disproportionately affect women. The order…
Bridging Suicidal Crisis to Outpatient Care: Could Ketamine Plus Buprenorphine Shift the Paradigm?
Original Source: Journal of Clinical Psychiatry, all rights reserved. — Acute suicidal crisis is a common, high-stakes presentation in emergency departments (EDs) across the US, with few treatment options for rapid and durable relief of symptoms. Due to the inconsistent availability of mental health care…
Diagnostic Complexity in Pediatric Autoimmune Encephalitis Presenting as Acute Psychosis: A Case Report
Autoimmune encephalitis (AE) is a neuroimmune disorder that may present in children and adolescents with predominantly psychiatric symptoms, leading to significant diagnostic challenges and overlap with primary psychiatric disorders. We describe a 13-year-old male with attention-deficit/hyperactivity disorder (ADHD) who presented with abrupt-onset insomnia, paranoia, visual…
Correction 65 (x) Xie_Xiang Part II
Reader inquiry called attention to “Optimizing Pharmacological Treatment in Children and Adolescents With Major Depressive Disorder: An Individual Participant Data Analysis” (Xiang et al. https://doi.org/10.1016/j.jaac.2026.05.010). In the supplement, the authors refer to the COD-FISH Tool, a peer-reviewed method developed by Drahota, Trivella, and Higgins, and…
Meta-Analytic Evidence of Clinical, Cognitive, Biological and Treatment Characteristics of Bipolar Spectrum Disorder in Children and Adolescents: Results From an Umbrella Review
To comprehensively synthesize the meta-analytic evidence regarding bipolar spectrum disorder (BSD) in children and adolescents. — Excerpt from Journal of the American Academy of Child & Adolescent Psychiatry Read More
Integrated Psychiatric Consultants
Office Hours:Mon-Fri, 9 a.m. - 5 p.m. CT